Wall Street analysts forecast that Celsion Co. (NASDAQ:CLSN) will announce ($0.31) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Celsion’s earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.29). Celsion posted earnings per share of ($1.96) during the same quarter last year, which would indicate a positive year-over-year growth rate of 84.2%. The company is expected to issue its next quarterly earnings report on Thursday, March 15th.
On average, analysts expect that Celsion will report full year earnings of ($2.46) per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.21) to ($1.08). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Celsion.
Celsion (NASDAQ:CLSN) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.17. The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 282.94% and a negative net margin of 4,292.80%.
A hedge fund recently bought a new stake in Celsion stock. Virtu Financial LLC acquired a new stake in shares of Celsion Co. (NASDAQ:CLSN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned 0.24% of Celsion at the end of the most recent quarter. 3.63% of the stock is currently owned by institutional investors and hedge funds.
Shares of Celsion (NASDAQ:CLSN) traded up $0.10 on Tuesday, hitting $2.22. The company had a trading volume of 240,700 shares, compared to its average volume of 436,028. The stock has a market capitalization of $35.02, a P/E ratio of -0.38 and a beta of 1.81. Celsion has a one year low of $1.24 and a one year high of $6.06.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/13/zacks-brokerages-expect-celsion-co-clsn-to-announce-0-31-eps.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.